Literature DB >> 10398103

Structural differences between valine-12 and aspartate-12 Ras proteins may modify carcinoma aggression.

F Al-Mulla1, E J Milner-White, J J Going, G D Birnie.   

Abstract

Recent evidence associates the codon 12 valine-for-glycine (G12V) mutant Ki-Ras protein with higher stage and increased lethality of colorectal carcinomas, while the codon 12 aspartate-for-glycine (G12D) Ras mutation shows no such association. Several observations may be relevant to this phenomenon. First, GTPase activity of G12V Ras is one-quarter that of G12D Ras and one-tenth that of wild-type (WT) Ras. Second, binding of the GTP analogue GppNp to G12D Ras is 8-fold weaker than its binding to G12V or WT Ras and crystal structures indicate that electrostatic repulsion between the carboxylate group of the G12D Asp-12 side-chain and the gamma phosphate of the bound nucleotide may make GTP binding to G12D Ras weaker even than that of GppNp. It is proposed that this lowering of affinity for GTP allows G12D Ras an escape from the oncogenic GTP-bound state, whereas GTP tightly bound to G12V mutant Ras generates a more persistent, potentially oncogenic, signal. Structural comparisons also suggest that differences between the Switch I (effector) region of G12D and G12V Ras could modify interactions with downstream signalling molecules such as Raf-1, neurofibromin, and phosphatidylinositol 3-hydroxy-kinase. Other differences between the G12D and G12V mutant Ras proteins include a lower affinity of the GTPase activating protein GAP for G12V than for G12D or WT Ras; but, as both G12D and G12V Ras are refractory to GTPase activation by GAP binding, this may be less significant. These studies complement experimental data showing that such Ras mutations differ in their effects in vitro and in vivo and, with recent data indicating heterogeneity of ras mutation in colorectal carcinomas and other tumours, make it plausible that codon 12 Ras mutations differ in carcinogenic potential and prognostic significance. Copyright 1999 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10398103     DOI: 10.1002/(SICI)1096-9896(199903)187:4<433::AID-PATH273>3.0.CO;2-E

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  44 in total

1.  Mutant K-ras2 in serum.

Authors:  H J N Andreyev; R Benamouzig; M Beranek; P Clarke; D Cunningham; A R Norman; W Giaretti; A F P M de Goeij; B J Iacopetta; E Jullian; K Krtolica; J Q Lee; S T Wang; N Lees; F Al-Mulla; O Muller; M Pauly; V Pricolo; A Russo; C Troungos; N Urosevic; R Ward
Journal:  Gut       Date:  2003-06       Impact factor: 23.059

2.  G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab.

Authors:  Ondrej Fiala; Tomas Buchler; Beatrice Mohelnikova-Duchonova; Bohuslav Melichar; Vit Martin Matejka; Lubos Holubec; Jana Kulhankova; Zbynek Bortlicek; Marie Bartouskova; Vaclav Liska; Ondrej Topolcan; Monika Sedivcova; Jindrich Finek
Journal:  Tumour Biol       Date:  2015-12-10

3.  An Unusual Combination: KRAS and BRAF Co-mutated Metastatic Colorectal Cancer.

Authors:  Narendranath Epperla; Ben George
Journal:  J Gastrointest Cancer       Date:  2016-06

4.  Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis.

Authors:  Georgios Antonios Margonis; Yuhree Kim; Gaya Spolverato; Aslam Ejaz; Rohan Gupta; David Cosgrove; Robert Anders; Georgios Karagkounis; Michael A Choti; Timothy M Pawlik
Journal:  JAMA Surg       Date:  2015-08       Impact factor: 14.766

5.  The crystal structure of the plant small GTPase OsRac1 reveals its mode of binding to NADPH oxidase.

Authors:  Ken-ichi Kosami; Izuru Ohki; Minoru Nagano; Kyoko Furuita; Toshihiko Sugiki; Yoji Kawano; Tsutomu Kawasaki; Toshimichi Fujiwara; Atsushi Nakagawa; Ko Shimamoto; Chojiro Kojima
Journal:  J Biol Chem       Date:  2014-08-15       Impact factor: 5.157

6.  Heterogeneous distribution of K-ras mutations in primary colon carcinomas: implications for EGFR-directed therapy.

Authors:  Satu Oltedal; Ole Gunnar Aasprong; Jannicke H Møller; Hartwig Kørner; Bjørnar Gilje; Kjersti Tjensvoll; Elke M Birkemeyer; Reino Heikkilä; Rune Smaaland; Oddmund Nordgård
Journal:  Int J Colorectal Dis       Date:  2011-05-15       Impact factor: 2.571

Review 7.  How many molecular subtypes? Implications of the unique tumor principle in personalized medicine.

Authors:  Shuji Ogino; Charles S Fuchs; Edward Giovannucci
Journal:  Expert Rev Mol Diagn       Date:  2012-07       Impact factor: 5.225

8.  KRAS Exon 2 Mutations as Prognostic Indicators in Advanced Colorectal Cancer in Clinical Practice: A Mono-Institutional Study.

Authors:  Vincenzo Dadduzio; Michele Basso; Sabrina Rossi; Tonia Cenci; Sara Capodimonti; Antonia Strippoli; Armando Orlandi; Eleonora Cerchiaro; Giovanni Schinzari; Alessandra Cassano; Maurizio Martini; Carlo Barone
Journal:  Mol Diagn Ther       Date:  2016-02       Impact factor: 4.074

9.  BRAF(V600E) efficient transformation and induction of microsatellite instability versus KRAS(G12V) induction of senescence markers in human colon cancer cells.

Authors:  Eftychia Oikonomou; Eleni Makrodouli; Maria Evagelidou; Tobias Joyce; Lesley Probert; Alexander Pintzas
Journal:  Neoplasia       Date:  2009-11       Impact factor: 5.715

10.  Experiences from treatment-predictive KRAS testing; high mutation frequency in rectal cancers from females and concurrent mutations in the same tumor.

Authors:  Mats Jönsson; Anna Ekstrand; Thomas Edekling; Jakob Eberhard; Dorthe Grabau; David Borg; Mef Nilbert
Journal:  BMC Clin Pathol       Date:  2009-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.